tiprankstipranks
Bellerophon (BLPH)
OTHER OTC:BLPH
Holding BLPH?
Track your performance easily

Bellerophon (BLPH) Stock Price & Analysis

502 Followers

BLPH Stock Chart & Stats


Financials

Annual

Ownership Overview

<0.01%99.98%
Insiders
<0.01% Other Institutional Investors
99.98% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

BLPH FAQ

What was Bellerophon’s price range in the past 12 months?
Bellerophon lowest stock price was $0.01 and its highest was $0.10 in the past 12 months.
    What is Bellerophon’s market cap?
    Currently, no data Available
    When is Bellerophon’s upcoming earnings report date?
    Bellerophon’s upcoming earnings report date is May 09, 2024 which is 228 days ago.
      How were Bellerophon’s earnings last quarter?
      Currently, no data Available
      Is Bellerophon overvalued?
      According to Wall Street analysts Bellerophon’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Bellerophon pay dividends?
        Bellerophon does not currently pay dividends.
        What is Bellerophon’s EPS estimate?
        Bellerophon’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Bellerophon have?
        Bellerophon has 68,907,000 shares outstanding.
          What happened to Bellerophon’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Bellerophon?
          Among the largest hedge funds holding Bellerophon’s share is Perceptive Advisors LLC. It holds Bellerophon’s shares valued at N/A.
            ---

            Bellerophon Stock Smart Score

            Company Description

            Bellerophon

            Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM. INOpulse is based on proprietary pulsatile nitric oxide delivery device. BCM is based on placebo-controlled clinical trial designed to support CE mark registration in the European Union. Bellerophon Therapeutics was founded in 2009 and is headquartered in Warren, NJ.
            ---
            Similar Stocks
            Company
            Price & Change
            Follow
            Avinger
            CASI Pharmaceuticals
            Corbus Pharmaceuticals
            Cyclacel Pharmaceuticals
            Popular Stocks
            ---
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis